Edgewise Therapeutics, Inc.
EWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $126,966 | $90,905 | $54,032 | $32,189 |
| G&A Expenses | $31,866 | $23,452 | $17,626 | $11,026 |
| SG&A Expenses | $31,866 | $23,452 | $17,626 | $11,026 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $158,832 | $114,357 | $71,658 | $43,215 |
| Operating Income | -$158,832 | -$114,357 | -$71,658 | -$43,215 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $25,019 | $14,194 | $4,018 | $402 |
| Pre-Tax Income | -$133,813 | -$100,163 | -$67,640 | -$42,813 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$133,813 | -$100,163 | -$67,640 | -$42,813 |
| % Margin | – | – | – | – |
| EPS | -1.45 | -1.57 | -1.26 | -0.86 |
| % Growth | 7.6% | -24.6% | -46.5% | – |
| EPS Diluted | -1.45 | -1.57 | -1.26 | -0.86 |
| Weighted Avg Shares Out | 92,415 | 63,724 | 53,594 | 49,500 |
| Weighted Avg Shares Out Dil | 92,415 | 63,724 | 53,594 | 49,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25,019 | $14,194 | $2,664 | $402 |
| Interest Expense | $0 | $0 | $4,018 | $0 |
| Depreciation & Amortization | $2,290 | $1,732 | $538 | $272 |
| EBITDA | -$156,542 | -$112,625 | -$71,120 | -$42,943 |
| % Margin | – | – | – | – |